NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
EXECUTIVE APPOINTMENTS AND PROMOTIONS IN THE HEALTHCARE INDUSTRY
John I. COOPER
Former GlaxoSmithKline VP Brings Global Manufacturing and Operational Management Expertise to ICN
ICN Pharmaceuticals Inc. has appointed John I. Cooper as executive VP of global manufacturing and supply. ICN, Costa Mesa, Calif., is a research based global pharmaceutical company that manufactures, markets, and distributes prescription and nonprescription pharmaceuticals.
Mr. Cooper is responsible for managing all manufacturing operations for the company, including supply and logistics operations, quality assurance, global procurement, reformulation operations, and all other areas relating to manufacturing and supply of ICN products worldwide.
Mr. Cooper most recently was VP of glob al operational excellence for GlaxoSmithKline.
Mr. Cooper received a B.S. degree in chemical engineering from the University of Kentucky and a master of science in business administration from Indiana University at South Bend. He also is a graduate of the senior executive development program from Notre Dame University.
Dr. Mehmood KHAN
Takeda Pharmaceuticals North America Appoints VP, Medical and Scientific Affairs
Mehmood Khan, M.D., F.A.C.E., has joined Takeda Pharmaceuticals North America Inc. (TPNA) as VP of medical and scientific affairs. In this position, Dr. Khan is responsible for leading all aspects of Lincolnshire, Ill. based TPNA’s medical and scientific affairs for Actos and future products developed and marketed by the company.
TPNA’s medical and scientific affairs department comprises several functions, including medical affairs, medical services, education and scientific affairs, clinical and scientific publications, and TPNA’s regional scientific managers.
Dr. Khan comes to TPNA from the Mayo Clinic in Rochester, Minn., where he most recently served as consultant physician in endocrinology and director of the diabetes, endocrine, and nutrition clinical trials unit in Mayo’s division of endocrinology. He earned his medical degree from the University of Liverpool Medical School, U.K., and completed a fellowship in clinical endocrinology in the Department of Medicine, University of Minnesota, Minneapolis.
Dr. Khan also has served on numerous state and national committees of the American Diabetes Association, the Minneapolis Medical Research Foundation, and the National Institutes of Health. Additionally, he held several visiting professorships, has published extensively, and presented at many medical meetings.
Dr. Catherine D. STRADER
Schering-Plough Research Institute Names Executive VP, Discovery Research
Schering-Plough Corp. has named Catherine D. Strader, Ph.D., executive VP of discovery research at Schering-Plough Research Institute (SPRI). Based in Kenilworth, N.J., SPRI is the pharmaceutical research and development arm of Schering-Plough Corp., a research based company engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide.
Dr. Strader, 48, is responsible for directing the activities of the discovery research organization, which includes biological research, chemical research, and technology acquisition and external collaboration.
Dr. Strader joined SPRI in 1995 as VP of biological research, cardiovascular, and central nervous system. Most recently she was senior VP of discovery biological research.
Before joining SPRI, Dr. Strader held positions of increasing responsibility at Merck & Co., including executive director of molecular pharmacology and biochemistry. Dr. Strader holds a Ph.D. in chemistry from the California Institute of Technology and a B.S. in chemistry from the University of Virginia.
Dr. Robert A. BEARDSLEY
Kereos Selects President and CEO
Kereos Inc., a St. Louis based biotechnology company developing targeted therapeutics and molecular imaging agents, has named Robert A. Beards ley, Ph.D., president and CEO. Dr. Beardsley also joins the board.
Dr. Beardsley was a cofounder and is a managing member of Simile Investors LLC, a private equity partnership focused on biotechnology investments, and serves on the board of directors of BioSeek Inc.
Before joining Kereos, Dr. Beardsley was acting CEO of MetaPhore Pharmaceuticals, a pharmaceutical research and development company. He also has held a number of positions in biotechnology and life sciences related companies, including bioStrategies Group Inc., Vector Securities International, and Enzyme Organics Inc. He holds a Ph.D. in biochemical engineering and a BSChE from the University of Iowa, along with a MBA from the University of Chicago.
Dr. Carson R. LOOMIS
Terry E. WILLARD
Norak Biosciences Announces Executive Promotions
Norak Biosciences Inc. has announced two pro motions within its executive ranks. Carson R. Loomis, Ph.D., has been promoted to senior VP of research and Terry E. Willard has been promoted to executive VP of the company. Norak Bio sciences, Morrisville, N.C., is a private biotechnology company that uses its proprietary Transfluor technology in the discovery and development of drugs that regulate G protein-coupled receptors.
Dr. Loomis is credited with developing Norak’s platform Transfluor technology from a benchtop academic assay to an automated and validated drug discovery technology. Transfluor is recognized as the state-of-the-art cell based assay for G coupled protein receptor (GPCR) drug discovery. Dr. Loomis was formerly VP of research, is a founding scientist, and has been a director of Norak since its inception. Previously, he was a cofounder and held executive positions at both Sphinx Pharmaceuticals and Xanthon Inc.
Mr. Willard joined Norak in January 2001 as VP of corporate and business development and is credited with developing and executing Norak’s commercial strategy for Transfluor. Before joining Norak, Mr. Willard held executive positions at King Pharmaceuticals, Medco Research, and Sonus Pharmaceuticals.
Drug Delivery POOL
Jade R. BROWN
Nastech Hires Senior Director, Marketing and Business Development
Nastech Pharmaceutical Co. Inc. has appointed Jade R. Brown as senior director of marketing and business development. Nastech, Bothell, Wash., is a leader in nasal drug delivery technology. Mr. Brown brings 13 years of pharmaceutical marketing and business development experience at Eli Lilly & Co. to Nastech.
In this newly created position, Mr. Brown’s responsibilities include defining marketing strategy, setting goals, and directing operational activities for Nastech’s drug delivery and pharmaceutical product pipeline. In addition, he plays an integral role in identifying, qualifying, contacting, and negotiating new business opportunities with pharmaceutical companies.
Before joining Nastech, Mr. Brown held various senior marketing and business development positions at Eli Lilly. Most recently, he served as brand director of women’s health, where he was responsible for all premarket activities to ensure the successful launch for Duloxetine, a new stress urinary incontinence compound, including a worldwide collaboration with Boehringer Ingelheim.
Mr. Brown was the recipient of numerous awards at Eli Lilly, including the President’s Award for business development contributions, the highest internal award at Eli Lilly, and the “Best Marketing Plan” in 2001 and 2002. He received a B.S in business from Indiana University in 1990 and a MBA from Harvard in 1996.
Gregory D. PHELPS
Ardais names CEO
Gregory D. Phelps has been appointed CEO of Ardais Corp., Lexington, Mass., a clinical genomics company that provides products and services for drug discovery. Mr. Phelps has more than 25 years of biotechnology and healthcare industry experience, with a track record for commercializing therapeutic products and innovative technologies, as well as building successful businesses.
Mr. Phelps most recently served as vice chairman of Dyax Corp., where he was responsible for corporate development activities. He remains a director of Dyax. His industry experience includes a senior managerial role at Baxter Travenol Laboratories and executive positions at Dyax Corp. and Genzyme Corp. Among his responsibilities as executive VP at Genzyme, Mr. Phelps provided leadership for the worldwide market launch of Ceredase and its recombinant form, Cerezyme, for the treatment of Gaucher disease.
Mr. Phelps received his MBA from the Harvard Graduate School of Business Administration and his B.S. from Bradley University.
Dr. Charles CARIGNAN
Boston Scientific Appoints Medical Director and VP, Clinical Affairs, Endosurgery
Charles Carignan, M.D., has been appointed to the newly created position of medical director and VP of clinical affairs for Boston Scientific Corp.’s endosurgery group. Boston Scientific, Natick, Mass., is a worldwide developer, manufacturer, and marketer of medical devices.
Dr. Carignan is responsible for the planning, development, and implementation of the endosurgery group’s worldwide practices, policies, and processes for medical and clinical affairs. His principal focus is improving endosurgery’s clinical trial strategy to increase the speed of new product development and assessments of new medical device technology. He also is developing the company’s product submission strategies.
Previously, Dr. Carignan was VP of clinical research and medical affairs at Conceptus.
Dr. Carignan earned his bachelor’s degree from Yale University. He received his medical degree from the College of Physicians and Surgeons of Columbia University and trained in general surgery at Columbia Presbyterian Medical Center.
Larry C. HEATON II
Curon Medical Names President and CEO
Larry C. Heaton II has joined Curon Medical Inc., Sunnyvale, Calif., as president, CEO, and a member of the board. Curon Medical develops, manufactures, and markets innovative proprietary products for the treatment of gastrointestinal disorders.
Mr. Heaton is a 20year veteran of the healthcare and medical device industry. Most recently, Mr. Heaton served as president, CEO, and a director of Response Genetics Inc., an applied genomics startup firm pro viding contract research and clinical trial gene expression services to the pharmaceutical industry.
Dr. H. Joseph REISER
Locus Discovery Selects President and CEO
Locus Discovery Inc. has appointed H. Joseph Reiser, Ph.D., president and CEO and as a board member. Locus, Blue Bell, Pa., is a privately held pharmaceutical company focused on developing novel, small molecule therapeutics.
Dr. Reiser has more than 22 years’ experience in the pharmaceutical and biotechnology industries. Dr. Reiser most recently was president and CEO of Cytogen Corp. and will continue to serve on its board of directors. During his nearly five-year tenure at Cytogen, Dr. Reiser successfully positioned the company as a product-driven, oncology-focused organization with a promising pipeline for the treatment of prostate and other cancers. Dr. Reiser gained pharmaceutical industry experience at Berlex Laboratories, where he held positions of increasing responsibility in research and development, business development, and marketing and sales, culminating in his appointment to corporate VP and general manager of pharmaceuticals and member of the board. Dr. Reiser was the recent chairman of the Biotechnology Council of New Jersey.
Lawrence I. GLASS
Panacea Pharmaceuticals Appoints Chief Strategy Officer
Panacea Pharmaceuticals Inc. has appointed Lawrence I. Glass to the position of chief strategy officer. In this new position, Mr. Glass is responsible for the development of strategic plans that address and integrate all major segments of the company, including product development, operational, legal, and financial activities. Panacea, Gaithersburg, Md., is an emerging biopharmaceutical company focused on using functional genomics and proteomics to develop therapeutics and diagnostics for diseases with substantial unmet clinical need.
Mr. Glass is a manager, strategist, and scientist with more than 20 years of experience in the life science industry. The primary emphasis of his career has been on business and corporate development, building and directing biomedical research, and drug development programs. His particular expertise is in developing inter-disciplinary programs that integrate laboratory and clinical R&D with corporate development strategies.
Mr. Glass served as executive VP for corporate development and scientific affairs for Virco Lab Inc., the U.S. subsidiary of Virco Group. Before that, he spent nearly 20 years at SRA Life Science Inc., which was acquired by Virco in late 2000.
Linda E. HATT
J. Knipper & Co. Buyback Leads to Senior Management Changes
Key senior management additions and pro motions have been made at J. Knipper & Co. The Lakewood, N.J. based company, which provides a broad array of healthcare marketing support services, was reacquired from McKesson Corp. in October 2002 by Jim Knipper, who remains president and CEO.
With this movement back to private ownership, Glenn Alexander has been hired as senior VP of finance. Mr. Alexander is responsible for the financial management of the company, with a focus on strategies and structures to support the growth of the company.
In addition, the company has hired Linda E. Hatt, Esq., as senior VP and general counsel. Ms. Hatt’s responsibilities focus on the legal, regulatory, and HR areas of the firm. She comes from McKesson Corp. where she was VP of legal services.
David Merkel has been promoted to senior VP of operations and information services. He has been with the company for eight years and has been a driving force in the rapid buildup of the IT center of the company.
Claire A. KLEPNER
Kathryn Hamilton PUCCI
Thomson Physicians World Announces Staff Additions
Thomson Physicians World has announced staff additions to the company’s headquarters in Secaucus, N.J., and its new Chicago location.
Theresa Brun, director of Lilly Client Services, joins Thomson Physicians World following a five-year tenure as president of the National Multiple Sclerosis Society, Indiana State Chapter. Her office is located within the Lilly Corporate Center in Indianapolis, where she has direct liaison responsibility for the Lilly Lecture Bureau.
Linda Lyons, program director, joins Thomson Physicians World from Discovery International, where she was a project manager. Ms. Lyons is based at Thomson Physicians World’s new Chicago office.
Kathleen Riedell, program director at Thomson Physicians World formerly was program director of publications at Ingenix. Ms. Riedell is based in the Chicago office.
Kenneth Paprockas, program manager, joins Thomson Physicians World from Discovery International, where he was medical education program manager. Mr. Paprockas is based in Chicago.
There also have been several appointments at Thomson GeoMed Global Communications, a division of PW.
Claire A. Klepner, VP of client services, brings nearly 30 years of pharmaceutical experience, having held positions in medical education and advertising, and preclinical and clinical research. As VP of client services for GeoMed, Ms. Klepner supervises internal account teams, develops and maintains client relationships, and oversees new business development.
Martha Shoup, program director, formerly was a senior account manager at Comprehensive Medical Communications.
Jodi Andrews, program manager, previously was an account manager at Discovery East (formerly Ventiv Health Communications).
Kathryn Hamilton Pucci, executive editor, joins GeoMed from Regan Campbell Ward, where she was editorial director.
Lane Lenard, senior medical writer, formerly was a freelance writer based in Millstone Township, N.J.
Kathleen Major, senior managing editor, previously was a managing editor of Accounting Today, which is published by the Accountants Media Group of The Thomson Corp.
Charles H. BEARDSLEY
Senior VP, Marketing and Sales, Position Filled at OmniComm
OmniComm Systems Inc., a developer of Web based technology that streamlines clinical-trial data gathering and validation processes, has appointed Charles H. “Rusty” Beardsley to the position of senior VP of marketing and sales. He oversees the Fort Lauderdale, Fla. based company’s strategy development and coordination of the global marketing and sales efforts, provides strategic direction for Omni Comm’s products and services, and directs all marketing and sales functions for OmniComm, including account management.
Mr. Beardsley brings to OmniComm a successful track record as a top executive in the pharmaceutical and information technology industries. Before joining OmniComm, he served as VP of U.S. marketing and sales at RhonePoulenc Rorer and later as president and general manager of RPR Canada. While at RPR (U.S.), he participated in two mergers and successfully led his sales and marketing teams through challenging periods of growth.
Dr. John ROOTENBERG
Business and Client Services Expert Joins Front Line Strategic Consulting
Front Line Strategic Consulting Inc., a leader in strategic consulting and market analysis for the life science industry, has added staff to its consulting and market reports groups.
John Rootenberg , M.D., joins San Mateo, Calif. based Front Line as managing consultant. Previously, Dr. Rootenberg provided management consulting and client services for more than 14 years in health care, information technology, and financial services. Most recently, he was cofounder and chief strategy officer for Freesamples.com, a marketing and research company that develops methods for sampling consumer products, as well as pharmaceuticals in conjunction with providers, pharmacies, and drug makers. Dr. Rootenberg received his B.S. in biochemistry and cell biology from the University of California, San Diego, and was a Ph.D. candidate at Stanford University School of Medicine; he received his medical doctorate from Tulane University School of Medicine.
Other new additions include Charles Chang, to the position of analyst for strategic market reports. Mr. Chang received his bachelor of arts in economics and molecular and cell biology/neurobiology from the University of California at Berkeley. Rochelle Ellis also joins as an analyst for strategic market reports. Ms. Ellis received her bachelor of arts degree in psychology with coursework in biology from Stanford University at Stanford, Calif.
Dr. Patricia A. CLEVELAND
Covalent Group Appoints VP of Global Regulatory Affairs
Covalent Group Inc. has appointed Patricia A. Cleveland, Ph.D., to the position of VP of global regulatory affairs. Covalent, Wayne, Pa., is a comprehensive research management and drug development organization supporting the pharmaceutical, biotechnology, and medical device industries. Dr. Cleveland oversees the regulatory affairs, medical writing, and pharmacovigilence functions at the company.
Dr. Cleveland joins Covalent Group from Celltech R&D PA LLC where, most recently, she was VP of regulatory affairs. From 1988 to 1998, Dr. Cleveland held a series of increasingly responsible assignments within the regulatory affairs units at GlaxoSmithKline, including leading the submission of the NDA for Tagamet-CR.
Dr. Cleveland has extensive experience in working with the U.S. Food and Drug Administration’s Centers for Drug Evaluation and Review and Biologics Evaluation and Review regarding approvals for regulatory submissions covering investigational new drugs, biologic license applications, and new drug applications. She has supervised numerous FDA meetings as well as organized and supervised 20 submissions covering NDAs, BLAs, and INDs in numerous therapeutic areas.
Paul S. COGGIN
Leader Chosen for Consulting Operations at Compass Strategic Consulting
Compass Strategic Consulting Inc . , a provider of commercial research and management strategies for life science organizations, has appointed Paul S. Coggin as VP and managing partner and a member of the executive committee. In this new position, Mr. Coggin is responsible for leading the New Haven, Conn. based company’s business analysis research team, overseeing project management and delivery, and developing and marketing new products.
Mr. Coggin holds a B.S. from Worcester Polytechnic Institute, a M.S. from the University of California Davis, and a MBA from the Yale School of Management.
In addition, he holds a position as an adjunct professor at the University of Bridge port and is an elected commissioner in East Norwalk, Conn.
Dr. Ralph D’AGOSTINO
Dr. Joseph MASSARO
Harvard Clinical Research Institute Selects Two Executives for Data Management and Biostatistics
Harvard Clinical Research Institute (HCRI), an applied clinical science center that provides integrative resources to support clinical trials and other clinical research, has appointed Ralph D’Agostino, Ph.D., as executive director of data management and biostatistics, and Joseph Massaro, Ph.D., as managing director of data management and biostatistics. HCRI, Boston, is a nonprofit joint venture of Harvard Medical School and the CareGroup and Partners Healthcare organizations, that works with industry sponsors to advance patient care through clinical research.
Dr. D’Agostino is an internationally recognized expert in the areas of longitudinal data analysis, biostatistics, clinical trials, and robust procedures.
Dr. D’Agostino is the director of the statistics and consulting unit and executive director of the M.A./Ph.D. program in biostatistics at Boston University.
He also is co-principal investigator and director of data management and statistical analysis of the 50year old Framingham Heart Study. Dr. D’Agostino has been affiliated with the FDA since 1974 as a consultant to the Biometrics Division of CDER and a member of the FDA’s Drugs and Devices Advisory Committees, including the Cardio Renal, GI, Drug Abuse, and Nonprescription Drugs Advisory Committee.
Dr. Massaro was director of statistical operations at the Cambridge office of Quintiles. While at Quintiles he was responsible for managing biostatistics, SAS programming, and data management operations.
Most recently he has consulted in the pharmaceutical and biotechnology industries and served with Dr. D’Agostino in support of the Framingham Heart Study and the Center for Psychiatric Rehabilitation.
Dr. Massaro is an assistant professor at Boston University and an adjunct professor at Massachusetts General Hospital Institute of Health Professionals.
Paul F. DELISLE
The Center for Advanced Medical Education hires VP
The Center for Advanced Medical Education Inc. has hired Paul F. DeLisle as VP. The center is a N.J.–based nonprofit education company and an accredited provider of continuing medical and pharmaceutical education that specializes in developing educational activities for healthcare professionals.
Mr. DeLisle has more than 25 years’ experience in pharmaceutical marketing, medical education, and strategic planning, along with a familiarity with ACCME, AMA, FDA, and PhRMA guidelines.
Most recently, he was a VP and group account supervisor at Interlink Healthcare Communications, where he managed agency teams and client portfolios.
Before joining Interlink, he served as general manager of Promex Medical, where he managed a 115-person workforce. Mr. DeLisle holds a bachelor of arts degree in marketing and business administration from Grand Valley State University.
VP, Operations, Joins MediciGroup
Lisa Fell has been appointed VP of program operations at Medici Group, a patient-directed communications company specializing in patient-centric recruitment and retention programs for clinical trials. Ms. Fell directs project management and operations related to patient recruitment, including strategy development, media planning and forecasting, performance metrics, and call center operations. The appointment reflects King of Prussia, Pa. based Medici Group’s growth and success in providing patient recruitment and retention to the glob al clinical trial community.
Ms. Fell brings more than 20 years of marketing and media related experience to her new position. Most recently, she served 13 years as VP at Harmelin Media, a national media-buying agency. Under her leadership, Harmelin represented MediciGroup’s media placement for the past five years. Ms. Fell supervised media planning, buying, budget tracking, and media response analysis for all MediciGroup’s clinical trial recruitment projects.
ClinPhone Expands U.S. Team With Business Development Director
ClinPhone Inc., a provider of intelligent eClinical Trial Management solutions for the biotechnology and pharmaceutical industries, has appointed Jeff Flecken as director of business development.
Mr. Flecken brings a thorough understanding of the pharmaceutical industry to ClinPhone, and further solidifies the company’s U.S. senior management team. ClinPhone is based in Nottingham, U.K, with U.S. offices in Chicago, Princeton, N.J., and San Francisco.
Mr. Flecken’s role is to oversee all U.S. business development initiatives and develop and implement strategies to achieve the company’s financial goals. He also assumes overall responsibility for the daily management of the U.S. business development team, implements strategies designed to develop customer relationships, and contributes to ClinPhone’s strategic direction.
Mr. Flecken brings more than 20 years of pharmaceutical business development experience to the company, most recently serving as VP of sales and marketing for a midsized clinical research organization.
Lisa A. GALLAGHER
URAC Hires Senior VP to Expand Information and Technology Accreditation
URAC, Washington, D.C., has hired Lisa A. Gallagher as senior VP of information and technology accreditation. Ms. Gallagher, an expert in information security, creates and manages a series of information-focused accreditation programs.
Ms. Gallagher has worked in security analysis, development of certification and accreditation guidance and plans, security engineering process definition, and the development of a capability maturity model for security engineering. Most recently, Ms. Gallagher served as senior director of the Healthcare Security Initiative, Global Security Practice, for Exodus, a cable and wireless service. Ms. Gallagher is a certified trust technology evaluator and has a bachelor of science in electrical engineering.
PDI Pharmaceutical Products Group Creates VP, Product Marketing, Position
John Gill has been promoted to head of product marketing for PDI Inc.’s Pharmaceutical Products Group. PDI, Upper Saddle River, N.J., is a commercial partner providing sales and marketing solutions to the biopharmaceutical and medical devices and diagnostics industries.
As VP of product marketing, Mr. Gill manages the marketing efforts on the products for which PDI has significant commercial responsibility. The PDI PPG’s primary focus is to license, acquire, and co-promote products and use its existing, broad-based infrastructure to generate profitable brand sales growth.
Mr. Gill joined PDI two years ago and launched PDI’s efforts in support of Ceftin. Before joining PDI, Mr. Gill worked in marketing positions with Bayer, SmithKline Beecham, and Bristol-Myers Squibb.
Growthink Names President
Corey Lavinsky has been named president of Growthink Research. The Venice, Calif. based venture capital firm develops strategic business plans, financial models, and investor presentations for growing ventures.
Mr. Lavinsky gained his expertise at Klutho, Cody & Kilo, P.C., a St. Louis-based law firm where for the past decade, he served as the firm’s primary contact for large-scale research and writing projects for products liability and commercial cases.
Mr. Lavinsky earned his bachelor’s degree from the State University of New York at Binghamton and his J.D. from the University of Missouri School of Law, where he was a member of the Missouri Law Review.
Cadient Fills Marketing Strategist Position
Cadient Group , an online pharmaceutical marketing company located in Conshohocken, Pa., has appointed Frank Moos to the position of marketing strategist.
A pharmaceutical advertising expert with more than 22 years of experience, Mr. Moos works with Cadient’s clients to develop online strategies that best achieve their marketing objectives while maximizing their ROI. He most recently was president and chief operating office of Creativity in Practice, a Saatchi &Saatchi company, where he spearheaded campaigns for Aventis, Solvay, GlaxoSmithKline, Merck’s Vaccine Division, Aventis Pasteur, and Dermik. Mr. Moos holds a B.A. in economics as well as a MBA, both from Temple University.
Dr. James W. BARNETT Jr
. Dr. W. Gary FLAMM
AAC Consulting Group Expands Food and Dietary Supplement Ingredient Safety Service Staff
AAC Consulting Group, the regulatory consulting subsidiary of Kendle International Inc., has entered into an exclusive relationship with W. Gary Flamm, Ph.D., and has hired James W. Barnett Jr. Ph.D., to further expand its services to the food and dietary supplement industries. Both toxicologists will assist AAC clients to determine the safety of food and dietary ingredients and to prepare submissions to the FDA for review and approval.
Dr. Flamm brings to AAC, Rockville, Md., more than 43 years of academic, government, and consulting experience. He is an internationally recognized expert and has been a Fellow in the Academy of Toxicological Sciences since 1999. Since retiring from the FDA in 1988 where he was the director of toxicological sciences, Dr. Flamm has provided consulting assistance to the regulated industry. Dr. Flamm earned his Ph.D. from the University of Cincinnati.
Dr. Barnett has 21 years of industry toxicology experience working for the Gulf South Research Institute, Monsanto Co., and Radian Corp. Most recently he was a consulting toxicologist in private practice. He has been a Diplomate of the American Board of Toxicology since 1985. He earned his Ph.D. from the University of Texas Medical Branch.
Intellisphere Names PR and Association Management Director
Intellisphere LLC, publishers of MD net nuide, Oncology net guide, and their related journals, has tapped James O’Brien as senior director of public relations and association management. The new position is designed to raise brand awareness for MD net guide and deepen the relationship between Plainsboro, N.J. based Intellisphere, state medical societies, and other healthcare associations.
Mr. O’Brien formerly was the president and CEO of Impact Strategies Inc., an integrated marketing and political consulting agency based in Washington, D.C. He also produced the independent film “DC Down” before joining Intellisphere.
Jin Li ALLEN
Senior VP, Corridor Operations, Joins Torre Lazur McCann Healthcare Worldwide
Torre Lazur McCann Healthcare Worldwide has appointed Jin Li Allen as senior VP of corridor operations. With headquarters in Parsippany, N.J., Torre Lazur McCann Healthcare Worldwide is a healthcare communications network. Ms. Allen is responsible for the operational management of the collection of integrated healthcare communication agencies within the Torre Lazur McCann Worldwide network. In addition to her global operational responsibilities, Ms. Allen also is involved in the mergers and acquisitions process.
Ms. Allen previously worked for the agency as general manager and director of client services in Shanghai, China. Before returning to Torre Lazur McCann Healthcare Worldwide, Ms. Allen was VP and director of client services at Ribotsky Worldwide and VP of healthcare at Porter Novelli. Ms. Allen is a graduate of Santa Clara University with a B.S. in biology, and of the University of California, Berkeley with a certificate in marketing.
inChord Agencies Announce Promotions and Hires
inChord Communications Inc., one of the largest independent marketing communications organizations in the world, and two of its agencies have made staff additions and changes.
Marcia Frederick, formerly corporate communications supervisor, has been promoted to director of corporate communications.
Ms. Frederick is responsible for leading internal communications and media relations for the seven companies under the inChord company umbrella.
Blue Diesel, an inChord subsidiary and one of the nation’s leading interactive marketing companies, has promoted a number of staff members.
David Kinne has been named account director. In this role, Mr. Kinne supervises the overall strategic plans and initiatives for several of Columbus, Ohio based Blue Diesel’s pharmaceutical accounts and works to identify additional opportunities for growth. Mr. Kinne holds a bachelor’s degree in biology from Emory University in Atlanta.
John Walsh has been appointed Blue Diesel’s VP of strategic development. As VP, Mr. Walsh is responsible for driving new business efforts for Blue Diesel as well as working with the other inChord companies to identify additional opportunities for the company.
Mr. Walsh holds a bachelor’s degree in management information systems from Indiana University of Pennsylvania and a certificate of project management from Penn State University. He also is a founding member of the Internet Executive Council formed in 1998 and PhRMA Internet Workgroup established in 1996.
Stacey Beeler, formerly senior multimedia designer, has been named art director. In this role, Ms. Beeler works closely with clients to develop creative concepts, multimedia presentations, and digital videos. She also directs photographers and illustrators and reviews work of multimedia designers. Holly Clark, formerly eMarketing analyst, has been named eMarketing manager. In this role, Ms. Clark works with sales and client services to research and develop interactive marketing strategies.
Sean Cowan, formerly senior art director, has been named associate creative director. In this role, Mr. Cowan oversees the visual design of the creative group and helps lead the creative visions for the company.
Matt Means, formerly senior interactive designer, has been named art director. Mr. Means works closely with clients to develop creative concepts, multimedia presentations and digital videos.
Jennifer Louie has been named account manager at the agency. She is responsible for strategic leadership, technology implementation, and project management for her assigned accounts. Ms. Louie holds a bachelor’s degree in biology with a concentration in marketing from Boston College in Chestnut Hill, Mass.
In other inChord news, Columbus, Ohio based Gerbig, Snell/Weisheimer, a full-service marketing and advertising agency, has promoted members of its staff.
Doug Mills has been promoted to VP and account director. In this role, Mr. Mills is responsible for supervising the strategic and tactical development, integration, and execution of the marketing and advertising programs for several specific healthcare accounts.
He holds a bachelor’s degree in marketing from Miami University located in Oxford, Ohio.
Dan Braun, formerly account coordinator, has been named account executive. He is responsible for all day-to-day account management and also is the primary contact for the client.
Matt Brown, formerly account supervisor, has been named account director. He oversees all aspects of one of GSW’s pharmaceutical accounts, from managing the client-agency relationship to being key in the development of the client’s tactical plan.
Allison Flynn, formerly senior account executive, has been named account supervisor. She serves as liaison between the client and creative team for one of GSW’s pharmaceutical accounts.
Trisha Heinfeldt, formerly art director, has been named senior art director. She is responsible for concept, design, presentation, and production of all projects for assigned accounts.
John Hofmeister, formerly creative team leader, has been named associate creative director. He is responsible for managing overall quality, deadlines, and budgets of creative work for one of GSW’s pharmaceutical accounts.
Nandi Houston, formerly account coordinator, has been named account executive. She is responsible for the day-to-day account workload for one of GSW’s pharmaceutical accounts and also is the primary contact for the client.
Nicole Maurus, formerly account executive, has been named senior account executive. She serves as liaison between the client and creative team for one of GSW’s pharmaceutical accounts.
Jennifer Mullett, formerly account executive, has been named senior account executive. She serves as liaison between the client and creative team for one of GSW’s pharmaceutical accounts.
Abby Scott, formerly associate art director, has been named art director. She manages concept, design, presentation, execution, and production of all projects for one of GSW’s pharmaceutical accounts.
Stephanie Stone, formerly associate art director, has been named art director. She manages concept, design, presentation, execution, and production of all projects for one of GSW’s pharmaceutical accounts.
Anne Strayer, formerly account executive, has been named senior account executive. She serves as a liaison between the client and creative team for one of GSW’s pharmaceutical accounts.
Dorland Global Health Communications Promotes Five, Hires Two
Dorland Solutions, a business unit of Dorland Global Health Communications, has announced five promotions and two hires. Dorland Solutions, Philadelphia, manages a wide range of diagnostic, device, biotechnology, and pharmaceutical clients.
John Lambdin has been promoted to senior VP and management supervisor. In his new position, Mr. Lambdin continues to supervise business on the BSNJOBST and Geneva Pharmaceuticals accounts in addition to offering leadership on new business projects.
Diane Carpentier has been promoted from account supervisor to VP and account supervisor. She continues to oversee the Cytyc Corp. account, including brand management of the ThinPrep PapTest.
Julie Morse has been promoted from assistant account executive to account executive. Ms. Morse joined the advertising agency in 2002 and has worked on multiple accounts, including Cytyc Health, HOYA, and Cardinal Health.
Alex Kang has been promoted from account coordinator to senior account coordinator. Mr. Kang continues to offer services to the VISX account and manage client communication.
Jill Polsky has been promoted to senior account coordinator. Ms. Polsky works on the Cytyc Corp. account and plays an instrumental role in new business.
Kevin Benoit joins Dorland Solutions as a senior account executive and oversees client projects for the BSNJOBST and Geneva Pharmaceutical accounts.
Before joining Dorland, Mr. Benoit was an account executive at the Hal Lewis Group in Philadelphia.
Andrea Bold joins the Dorland Solutions team as an account executive, focusing on the Cytyc Corp. account. Ms. Bold previously was at Toltzis Communications.
Lauren Gersten CHEKANOW
Stephen VELASQUEZ Jr.
Healthworld Communications Group Announces Promotions and Additions to Consumer and Professional Staff
Healthworld Communications Group, New York, has announced promotions and additions to its staff at the consumer and professional advertising divisions. Healthworld Communications Group is an international communications organization specializing in healthcare.
Joining Healthworld’s consumer division as senior VP and management supervisor is David Lavietes. Previously, he was a senior partner and group account director at Ogilvy One.
In addition, Lauren Gersten Chekanow joins the foodservice division of Healthworld as account supervisor.
Before joining Healthworld, she was an account executive at The Food Group, a subsidiary of WPP.
In the consumer division, Wendy Peterson has been promoted from account executive to account supervisor.
Also in the consumer division, Lucie Shin moves from assistant account executive to account executive.
Adrian Sansone, formerly part of the medical education division of Healthworld, joins the global business division as VP and executive director.
In the professional division, Stephen Velasquez Jr. has been promoted from account executive to senior account executive.
Palio Communications Expands Staff
Palio Communications, a full-spectrum advertising and communications agency, has appointed Christina Culbert as VP and account director of medical strategies, Paul Harrington as group copy supervisor, Jody Hayes as account executive, and Renee McAllister as project manager.
Ms. Culbert has extensive experience in pharmaceutical brand management, product launches, thought leader development, sales force training and support, and Internet/digital solution implementation.
She comes to Sarasota Springs, N.Y. based Palio from PGI MedCom, where she served as VP of account services. In that role she was responsible for the management of a number of large client accounts, including Viagra, Lantus, and Pravachol.
Ms. Culbert holds a bachelor’s degree and master’s degree from the University of Notre Dame.
Mr. Harrington joins Palio from the agency Rockett, Burkhead & Winslow, where he served as senior VP and managing creative director.
In that position Mr. Harrington was responsible for day-to-day creative operations and served as lead writer on an assortment of consumer, high-tech, B2B, and healthcare accounts.
Mr. Harrington received his master’s degree from the University of Rochester and his bachelor’s degree from Boston College.
Ms. Hayes has held a number of varied positions in the pharmaceutical and healthcare industries.
Most recently she served as an HIV sales specialist at Boehringer-Ingelheim Pharmaceuticals, where she promoted virology pharmaceutical products to infectious disease specialists in HIV.
Ms. Hayes received her master’s in business administration from Sage Graduate School and her bachelor’s degree from Siena College.
Ms. McAllister brings to her project management position extensive experience in all areas of project management, including production, technology, and administration.
She comes to the healthcare advertising from WNYTTV/13, where she served as continuity coordinator. In that position, she processed commercials to air and acted as a liaison between the traffic, production, and engineering departments.
Ms. McAllister received her bachelor’s degree from the State University of New York at Buffalo and her associate’s degree from the Sage College of Albany.
Quantum Group Promotes Two Within Account Management Ranks
The Quantum Group, CommonHealth’s agency dedicated exclusively to building consumer healthcare brands, has announced pro motions within its account management team. CommonHealth is a leading healthcare communications resource and a WPP Group company.
Catherine Goss has been promoted to VP and account supervisor from account supervisor. In this expanded position, she is responsible for overseeing the development and maintenance of client-brand strategies.
Additionally, Ms. Goss serves as liaison to sister CommonHealth agencies to ensure that an integrated brand identity is achieved for her accounts.
Ms. Goss’ career with The Quantum Group, Parsippany, N.J., began in February 2002. Previously, she was employed with BBDO as an account supervisor.
Emma Pearce has moved to account executive from assistant account executive. As an account executive, Ms. Pearce oversees the day-to-day tactical activities for her assigned accounts.
Ms. Pearce has been with The Quantum Group since 1997, the year the company was established.
Before joining the account management team, she was employed with the media-planning department.
Please send your personnel announcements to email@example.com.